NIH-Sponsored Trial of Lassa Vaccine Opens - Viral Hemorrhagic Disease Can be Fatal & Causes Permanent Hearing Loss ...

The NIH announced the beginning of a phase 1 first-in-human trial of a vaccine for Lassa fever, a potentially fatal viral hemorrhagic disease for which there is no approved vaccine or treatment.

Lassa fever vaccine is one step closer to approval. Lassa virus infections, primarily spread by rodents, can cause a fatal ...

An NIH-sponsored clinical trial of a candidate vaccine to prevent Lassa fever has begun enrolling participants.

A renowned virologist and former vice-chancellor of Redeemer’s University, Prof. Oyewale Tomori, has warned that Lassa fever ...

New research this month shows that the experimental antiviral obeldesivir prevented up to 100% of deaths in monkeys infected ...

The country is presently battling its eighth Ebola outbreak, confirmed by the Ministry of Health in January, with two ...

A day after getting exposed to the Ebola virus, ten monkeys then received an Obeldesivir pill daily for ten days, while three control monkeys received no treatment and died. The study found that ...

The NCDC on Wednesday, confirmed 563 Lassa fever cases out of the 2,960 suspected cases of the disease and 103 deaths as of ...

Symptoms can appear suddenly and include a fever, chills, severe headache, cough, muscle or joint pain. A new rule has been ...

Rarely if ever does a newspaper headline include the words “crisis averted,” yet, that is what investments in development ...

In this week’s edition of InnovationRx, we look at the policy uncertainty around vaccines, sex differences in GLP-1 drug side ...